drugset / Trial / NCT06433505
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
Non-randomizedSequentialOpen-labelTreatment
Summary
The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.
Timeline
- Start
- 2024-05-30
- Primary completion
- 2025-02-14
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986410 | Unknown | — | — |
| Subject | CC-94676 | Other / unclassified | — | — |
| Subject | GRIDEGALUTAMIDE | Small molecule | — | — |
Indications
No indication recorded.